- Poster presentation
- Open Access
Role of gadolinium enhanced cardiac magnetic resonance in recent onset non-ischemic cardiomyopathy: a systematic review and metanalysis
© Eifer et al; licensee BioMed Central Ltd. 2015
- Published: 3 February 2015
- Risk Ratio
- Cardiac Magnetic Resonance
- Late Gadolinium Enhancement
- Composite Endpoint
Cardiac magnetic resonance (CMR) late gadolinium enhancement (LGE) and early gadolinium enhancement (EGE) are powerful diagnostic tools for acute cardiomyopathies. LGE is associated with impaired prognosis in ischemic and in chronic non-ischemic cardiomyopathy (NICM), but the impact of gadolinium enhanced CMR on prognosis in recent onset NICM is less well established. We performed a systematic review with metanalysis to investigate the prognostic role of an abnormal contrast enhanced CMR in patients presenting with recent onset NICM.
From January 1994 to July 2014, Pubmed, EMBASE and additional bibliographic sources were searched for publications using contrast enhanced CMR (EGE and LGE) in patients with recent onset NICM, defined as symptoms onset within 6 months of presentation, including myocarditis, acute chest pain syndromes with normal coronaries, and idiopathic acute cardiomyopathy. We included articles that assessed total mortality and/or composite cardiovascular events (mortality plus any combination of cardioverter defibrillator implantation, cardiac transplantation, hospitalization or worsening heart failure) with a follow-up of least 3 months after the initial presentation. Data were independently extracted by 2 authors and pooled risk ratios (RR) were calculated using the DerSimonian and Laird random-effects method.
In patients presenting with recent onset NICM, the presence of an abnormal contrasted enhanced CMR is associated with a statistically significant increased risk ratio for composite endpoints. These findings may help identify those patients with a worse prognosis and increased use of medical resources.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.